Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Cholecystokinin (CCK) is a hormone secreted from I-cells of the gut, as well as neurons in the enteric and central nervous system, that binds and activates CCK-1 and CCK-2 receptors to mediate its biological actions. To date knowledge relating to the physiological significance of CCK has predominantly focused around induction of short-term satiety. However, CCK has also been highlighted to possess important actions in relation to the regulation of insulin secretion, as well as overall beta-cell function and survival. Consequently, this has led to the development of enzymatically stable, biologically active, CCK peptide analogues with proposed therapeutic promise for both obesity and type 2 diabetes. In addition, several studies have demonstrated metabolic, and therapeutically relevant, complementary biological actions of CCK with those of the incretin hormones GIP and GLP-1, as well as with amylin and leptin. Thus, stable CCK derivatives not only offer promise as potential independent weight-reducing and glucose-lowering drugs, but also as effective adjunctive therapies. This review focuses on the recent and ongoing developments of CCK in the context of new therapies for obesity and type 2 diabetes.
LanguageEnglish
Pages229-235
JournalPeptides
Volume100
Early online date3 Feb 2018
DOIs
Publication statusE-pub ahead of print - 3 Feb 2018

Fingerprint

Cholecystokinin
Medical problems
Type 2 Diabetes Mellitus
Obesity
Peptides
Therapeutics
Hormones
Cholecystokinin B Receptor
Islet Amyloid Polypeptide
Enteric Nervous System
Incretins
Glucagon-Like Peptide 1
Neurology
Leptin
Neurons
Cell Survival
Central Nervous System
Insulin
Derivatives
Weights and Measures

Keywords

  • Cholecystokinin (CCK)
  • glucagon-like peptide-1 (GLP-1)
  • glucose-dependent insulinotropic polypeptide (GIP)
  • amylin
  • leptin
  • insulin secretion
  • satiety
  • obesity
  • diabetes

Cite this

@article{1c2558e07f0543e193bd6cf96101d169,
title = "Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes",
abstract = "Cholecystokinin (CCK) is a hormone secreted from I-cells of the gut, as well as neurons in the enteric and central nervous system, that binds and activates CCK-1 and CCK-2 receptors to mediate its biological actions. To date knowledge relating to the physiological significance of CCK has predominantly focused around induction of short-term satiety. However, CCK has also been highlighted to possess important actions in relation to the regulation of insulin secretion, as well as overall beta-cell function and survival. Consequently, this has led to the development of enzymatically stable, biologically active, CCK peptide analogues with proposed therapeutic promise for both obesity and type 2 diabetes. In addition, several studies have demonstrated metabolic, and therapeutically relevant, complementary biological actions of CCK with those of the incretin hormones GIP and GLP-1, as well as with amylin and leptin. Thus, stable CCK derivatives not only offer promise as potential independent weight-reducing and glucose-lowering drugs, but also as effective adjunctive therapies. This review focuses on the recent and ongoing developments of CCK in the context of new therapies for obesity and type 2 diabetes.",
keywords = "Cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), amylin, leptin, insulin secretion, satiety, obesity, diabetes",
author = "V Pathak and Peter Flatt and Nigel Irwin",
year = "2018",
month = "2",
day = "3",
doi = "10.1016/j.peptides.2017.09.007",
language = "English",
volume = "100",
pages = "229--235",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier",

}

Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. / Pathak, V; Flatt, Peter; Irwin, Nigel.

In: Peptides, Vol. 100, 03.02.2018, p. 229-235.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

AU - Pathak, V

AU - Flatt, Peter

AU - Irwin, Nigel

PY - 2018/2/3

Y1 - 2018/2/3

N2 - Cholecystokinin (CCK) is a hormone secreted from I-cells of the gut, as well as neurons in the enteric and central nervous system, that binds and activates CCK-1 and CCK-2 receptors to mediate its biological actions. To date knowledge relating to the physiological significance of CCK has predominantly focused around induction of short-term satiety. However, CCK has also been highlighted to possess important actions in relation to the regulation of insulin secretion, as well as overall beta-cell function and survival. Consequently, this has led to the development of enzymatically stable, biologically active, CCK peptide analogues with proposed therapeutic promise for both obesity and type 2 diabetes. In addition, several studies have demonstrated metabolic, and therapeutically relevant, complementary biological actions of CCK with those of the incretin hormones GIP and GLP-1, as well as with amylin and leptin. Thus, stable CCK derivatives not only offer promise as potential independent weight-reducing and glucose-lowering drugs, but also as effective adjunctive therapies. This review focuses on the recent and ongoing developments of CCK in the context of new therapies for obesity and type 2 diabetes.

AB - Cholecystokinin (CCK) is a hormone secreted from I-cells of the gut, as well as neurons in the enteric and central nervous system, that binds and activates CCK-1 and CCK-2 receptors to mediate its biological actions. To date knowledge relating to the physiological significance of CCK has predominantly focused around induction of short-term satiety. However, CCK has also been highlighted to possess important actions in relation to the regulation of insulin secretion, as well as overall beta-cell function and survival. Consequently, this has led to the development of enzymatically stable, biologically active, CCK peptide analogues with proposed therapeutic promise for both obesity and type 2 diabetes. In addition, several studies have demonstrated metabolic, and therapeutically relevant, complementary biological actions of CCK with those of the incretin hormones GIP and GLP-1, as well as with amylin and leptin. Thus, stable CCK derivatives not only offer promise as potential independent weight-reducing and glucose-lowering drugs, but also as effective adjunctive therapies. This review focuses on the recent and ongoing developments of CCK in the context of new therapies for obesity and type 2 diabetes.

KW - Cholecystokinin (CCK)

KW - glucagon-like peptide-1 (GLP-1)

KW - glucose-dependent insulinotropic polypeptide (GIP)

KW - amylin

KW - leptin

KW - insulin secretion

KW - satiety

KW - obesity

KW - diabetes

U2 - 10.1016/j.peptides.2017.09.007

DO - 10.1016/j.peptides.2017.09.007

M3 - Article

VL - 100

SP - 229

EP - 235

JO - Peptides

T2 - Peptides

JF - Peptides

SN - 0196-9781

ER -